Theragenics to distribute Oncuras brachytherapy products

Theragenics has signed a non-exclusive agreement with Oncura to distribute its brachytherapy-related products in North America.

The one-year agreement is effective May 1 and provides for additional one-year terms upon mutual agreement of the parties, said the Buford, Ga.-based Theragenics.

Oncura, a unit of GE Healthcare, manufactures, markets and sells the iodine-125 based OncoSeed used in prostate cancer treatments.

Around the web

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.